RECRUITING Not applicable ClinicalTrials.gov

Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing

Sponsor: Assistance Publique - Hôpitaux de Paris • ClinicalTrials.gov ID: NCT07243249

Registry updated: 2026-09-08

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Respiratory infections are very common, especially during winter, and are often caused by viruses such as influenza, SARS-CoV-2 or respiratory syncytial virus (RSV). These illnesses are generally mild, but their symptoms do not always allow a clear distinction to be made between a viral infection and a bacterial infection. In the absence of a precise diagnosis, antibiotics may be prescribed when they are not necessary in many cases. However, the excessive use of antibiotics contributes to the development of bacterial resistance, which is a major public health issue. The aim of this study is to better understand whether the use of a rapid test (called TROD), which can quickly identify certain respiratory viruses, can help doctors reduce unnecessary antibiotic prescriptions for these infections. The test will be performed using a swab gently inserted into the nose.

Interventions

TROD (Diagnostic test)
Patient with triplex TROD test. Doctors may or may not prescribe antibiotics with the help of the results of triplex TROD tests.

Eligibility criteria

Inclusion Criteria: 1. Age ≥ 1 year 2. Presenting with: * Either fever (temperature \> 38°C measured by patient or physician) within the past 72 hours, and one of the following symptom combinations: 1. Rhinorrhea (white, yellow, or green discharge) and/or nasal obstruction, and cough 2. Body aches, cough, and fatigue 3. Odynophagia and negative strepto-test 4. Cough 5. Otalgia * Or suspicion of lower respiratory tract infection: signs of infection (respiratory rate \> 20/min, heart rate \> 100/min, fatigue, Body aches, chills, or fever), associated with pulmonary localization signs \[cough, sputum, chest pain, auscultatory abnormality (rhonchi, crackles, or wheezing)\] 3. Affiliation with the national health insurance system 4. Informed consent obtained from the adult participant, or from the person(s) with parental authority for a minor participant Exclusion Criteria: 1. Requirement for hospitalization 2. Presence of a non-respiratory infection requiring concomitant antibiotic treatment. 3. Patients covered by State Medical Aid (AME)

Conditions

Respiratory Infections Antibiotic

Locations

Assistance Publique - Hôpitaux de Paris — Garches, France

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment